Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• LlovetJMFusterJBruixJIntention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantationHepatology19993061434144010573522
   PubMed Web of Science ®Google Scholar
• BismuthHMajnoPEAdamRLiver transplantation for hepatocellular carcinomaSemin Liver Dis199919331132210518310
   PubMed Web of Science ®Google Scholar
• YaoFYFerrellLBassNMLiver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survivalHepatology20013361394140311391528
   PubMed Web of Science ®Google Scholar
• LlovetJMBurroughsABruixJHepatocellular carcinomaLancet200336293991907191714667750
   PubMed Web of Science ®Google Scholar
• BruixJShermanMAmerican Association for the Study of Liver DiseasesManagement of hepatocellular carcinoma: an updateHepatology20115331020102221374666
   PubMed Web of Science ®Google Scholar
• KimBKKimSUParkJYApplicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment – naive patients with hepatocellular carcinomaLiver Int20123271120112722524688
   PubMed Web of Science ®Google Scholar
• WilhelmSMCarterCTangLBAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisCancer Res200464197099710915466206
   PubMed Web of Science ®Google Scholar
• LlovetJMRicciSMazzaferroVSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
   PubMed Web of Science ®Google Scholar
• ChengALKangYKChenZEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialLancet Oncol2009101253419095497
   PubMed Web of Science ®Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• BruixJShermanMLlovetJMEASL Panel of Experts on HCCClinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the LiverJ Hepatol200135342143011592607
   PubMed Web of Science ®Google Scholar
• GillmoreRStuartSKirkwoodAEASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolizationJ Hepatol20115561309131621703196
   PubMed Web of Science ®Google Scholar
• KimBKKimSUKimMJNumber of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with ChemoembolizationClin Cancer Res201310.1158/1078-0432.CCR-12-2721
   Web of Science ®Google Scholar
• ShimJHParkJWChoiJIParkBJKimCMPractical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic areaJ Cancer Res Clin Oncol2009135461762518846384
   PubMed Web of Science ®Google Scholar
• VoraSRZhengHStadlerZKFuchsCSZhuAXSerum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinomaOncologist200914771772519581525
   PubMed Web of Science ®Google Scholar
• ShaoYYLinZZHsuCShenYCHsuCHChengALEarly alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinomaCancer2010116194590459620572033
   PubMed Web of Science ®Google Scholar
• KimBKAhnSHSeongJSEarly alpha-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinomaLiver Int201131336937621083802
   PubMed Web of Science ®Google Scholar
• LeeMHKimSUKim doYEarly on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinomaJ Gastroenterol Hepatol201227231332221793906
   PubMed Web of Science ®Google Scholar
• KawaokaTAikataHMurakamiEEvaluation of the mRECIST and alpha-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenibOncology201283419220022890083
   PubMed Web of Science ®Google Scholar
• PersoneniNBozzarelliSPressianiTUsefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinomaJ Hepatol201257110110722414760
   PubMed Web of Science ®Google Scholar
• OkuyamaHIkedaMKuwaharaAPrognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenibOncology201488424124625503567
   PubMed Web of Science ®Google Scholar
• da FonsecaLGBarroso-SousaRBento AdaSPre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenibMed Oncol2014311126425273866
   PubMed Web of Science ®Google Scholar
• LiXChenZHMaXKNeutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinomaTumour Biol20143511110571106325095975
   PubMedGoogle Scholar
• Korean Liver Cancer StudyGNational Cancer CenterKPractice guidelines for management of hepatocellular carcinoma 2009Korean J Hepatol2009153391423 Korean19783891
   PubMedGoogle Scholar
• VoucheMKulikLAtassiRRadiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenibHepatology20135851655166623703789
   PubMed Web of Science ®Google Scholar
• KurebayashiJNishimuraRTanakaKSignificance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective studyBreast Cancer200411438939515604995
   PubMedGoogle Scholar
• JangNYKangSBKimDWThe role of carcinoembryonic antigen after neoadjuvant chemoradiotherapy in patients with rectal cancerDis Colon Rectum201154224525221228676
   PubMed Web of Science ®Google Scholar
• FornerABruixJBiomarkers for early diagnosis of hepatocellular carcinomaLancet Oncol201213875075122738800
   PubMed Web of Science ®Google Scholar
• ChonYEChoiGHLeeMHCombined measurement of preoperative alpha-fetoprotein and des-gamma-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinomaInt J Cancer2012131102332234122362471
   PubMed Web of Science ®Google Scholar
• YamamotoKImamuraHMatsuyamaYSignificance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomyAnn Surg Oncol200916102795280419669841
   PubMed Web of Science ®Google Scholar
• ToyodaHKumadaTKaneokaYPrognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCCJ Hepatol200849222323218571271
   PubMed Web of Science ®Google Scholar
• ShettyKTimminsKBrensingerCLiver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcomeLiver Transpl200410791191815237377
   PubMed Web of Science ®Google Scholar
• LeeYKKimSUKim doYPrognostic value of alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolizationBMC Cancer201313523282286
   PubMed Web of Science ®Google Scholar
• ChenLTLiuTWChaoYAlpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinomaAliment Pharmacol Ther200522321722616091059
   PubMed Web of Science ®Google Scholar
• ChanSLMoFKJohnsonPJNew utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapyJ Clin Oncol200927344645219064965
   PubMed Web of Science ®Google Scholar
• WilhelmSMAdnaneLNewellPVillanuevaALlovetJMLynchMPreclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signalingMol Cancer Ther20087103129314018852116
   PubMed Web of Science ®Google Scholar
• TakedaHNishikawaHOsakiYJapanese Red Cross Liver Study GroupClinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in JapanLiver Int Epub5162014
   Web of Science ®Google Scholar